- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT02178397
A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR (FLARE)
The current first line treatment of patients with EGFR activating mutation lung cancer is EGFR TKI. Compared to platinum-based chemotherapy, EGFR-TKIs are superior in terms of response rate and progression-free survival. However, an acquired resistance occurs almost constantly. The second-line treatment includes platinum-based chemotherapy in the absence of contraindication. This chemotherapy is then administered after discontinuing EGFR TKIs.
However, a rebound phenomenon of the disease was described in patients who discontinued EGFR TKIs. Some clinical teams therefore recommend, as a precaution, in order to avoid any withdrawal phenomenon, to never discontinue EGFR TKIs in patients developing an EGFR TKI acquired resistance.
It seems therefore useful to conduct a study to better define the therapeutic strategy to adopt in patients developing an acquired resistance after having received EGFR TKIs as first line treatment.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Aix En Provence, Ranska
- CH
-
Amiens, Ranska
- CH
-
Angers, Ranska, 49933
- CHRU
-
Annecy, Ranska, 74374
- CH
-
Brest, Ranska, 29609
- CHU
-
Caen, Ranska, 14000
- Centre Francois Baclesse
-
Creteil, Ranska, 94000
- CHIC
-
Draguignan, Ranska, 83007
- CH
-
Elbeuf, Ranska
- CH
-
GAP, Ranska, 05007
- CHIC
-
La Roche/yon, Ranska
- Ch La Roche/Yon
-
Le MANS, Ranska, 72037
- Centre Hospitalier
-
Lille, Ranska, 59020
- Centre OSCAR LAMBRET
-
Limoges, Ranska, 87042
- CHU
-
Longjumeau, Ranska, 91160
- CH
-
Lorient, Ranska, 35632
- CH
-
Macon, Ranska, 71018
- CH
-
Mantes La Jolie, Ranska, 78201
- CH
-
Marseille, Ranska, 13273
- Institut Paoli Calmettes
-
Marseille, Ranska
- AP-HM - Hôpital Nord
-
Meaux, Ranska, 77104
- CH
-
Meulan, Ranska, 78250
- Centre Hospitalier Intercommunal
-
PAU, Ranska
- CH
-
Perpignan, Ranska
- Centre Catalan
-
Rennes, Ranska, 35033
- CHU
-
Roanne, Ranska
- CH
-
Rouen, Ranska
- CHU
-
Salon de Provence, Ranska
- CH
-
Sens, Ranska, 89100
- CH
-
St BRIEUC, Ranska
- CH
-
St ETIENNE, Ranska, 42271
- Institut de Cancerologie de La Loire
-
Strasbourg, Ranska, 67065
- Centre Paul Strauss
-
Tarbes, Ranska
- CH
-
Toulon, Ranska, 83041
- Hôpital d'Instruction des Armées Sainte-Anne
-
Villefranche, Ranska, 69655
- CH
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Man or woman aged 18 years or more
- Non-small cell lung cancer carcinoma (NSCLC) cytologically or histologically confirmed
- Measurable disease according to RECIST 1.1 criteria
- Life expectancy greater than 12 weeks
- Performance Status (ECOG) ≤ 2
- Stage IIIB considered ineligible for thoracic radiotherapy at "curative" doses or stage IV
- Presence of at least one measurable target lesion
- Documented disease progression (RECIST 1.1) after first line treatment with erlotinib, during at least 4 months in case of partial or complete response according to RECIST criteria, or 6 months in case of stable disease. The treatment with Erlotinib should not be discontinued for more than 8 days between the progression and the inclusion in the study. The daily dose of Erlotinib should be at least 50 mg.
- Presence of one of the EGFR activating mutations in the tumor (exon 19 deletion or L858R, G719X or L861Q)
- One additional line of previous chemotherapy is allowed if administered in adjuvant or neoadjuvant setting and received more than six months before.
- Prior radiotherapy is allowed if the volume of irradiated marrow is <25% of the total bone marrow. The prior radiotherapy must be completed at least two weeks before study entry
- Brain metastases are allowed if they are controlled without steroids and if their treatment is completed (radiotherapy and/or surgery). Patients with no symptomatic brain metastases may be included; even if brain metastases are progressive and even if they are the only site of progression (since the investigator considers that irradiation is not required). These metastases have not to be life-threatening (are excluded: cerebellar metastasis ≥ 2 cm, brainstem metastasis, brain metastasis > 3 cm and/or near important functional structure).
- Normal Liver function (bilirubin ≤ULN, AST - ALT ≤2.5 x ULN, alkaline phosphatase ≤3 x ULN), or in case of liver metastases: alkaline phosphatase, AST-ALT ≤ 5 x ULN
- Normal renal function: blood creatinine ≤ULN and / or creatinine clearance> 60 ml/min calculated with the MDRD formula
- Normal blood function: absolute neutrophil count ≥ 1.5 x 109/l and / or platelets ≥ 100 x 109 / l, hemoglobin> 9 g/dl
- Woman and man under efficient contraception during treatment and at least 6 months after the end of treatment by pemetrexed or platinum or gemcitabine
- Signed written Informed consent
Exclusion Criteria:
- Bronchoalveolar, mixed, neuroendocrine and small cell lung cancers
- Patient with only bone metastases are not eligible
- All progressive metastatic sites treated locally (surgery, radiotherapy)
- Superior vena cava syndrome
- Uncontrolled cardiac disease requiring treatment
- Congestive heart failure, angina pectoris, significant arrhythmias or history of myocardial infarction within the previous 12 months
- Neurological or psychiatric disorders
- Uncontrolled infectious disease
- Peripheral neuropathy grade≥ 2
- Definitive contraindication for the use of steroids
- Inductive anti-epileptic treatments (phenobarbital, phenytoïne)• Previous or concomitant other cancer, including skin cancer (except basal cell cancer of the skin), except in situ treated carcinoma of the cervix , except cancer treated with surgery alone without recurrence for 5 years
- Pregnant or breastfeeding woman
- Patient follow-up not achievable
- Participation in a trial within the last 30 days
- Patient deprived of liberty as a result of a justice or administrative decision
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: EXPERIMENTAL ARM B
INDUCTION chemotherapy: 4 cycles of
THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed in combination with erlotinib |
|
Active Comparator: STANDARD ARM A
INDUCTION chemotherapy: 4 cycles of
THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Efficacy by PFS
Aikaikkuna: From date of randomization until the date of first documented progression evaluated every 6-9 weeks
|
Efficacy will be assessed by the PFS, define as time between randomization of the patient in the study and disease progression (local, regional, distant and second cancer) or death (all causes).
Alive patients free of progression will be censored at the last follow-up.
|
From date of randomization until the date of first documented progression evaluated every 6-9 weeks
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
scores of QoL
Aikaikkuna: at 4 months after inclusion
|
difference between the scores of QoL at baseline and at 4 months after inclusion for the three targeted dimensions of EORTC QLQ-C30 (global quality of life, fatigue and physical functioning).
A difference or 10 points or more at 4 months after inclusion for one score between the 2 arms will be considered as clinically relevant.
|
at 4 months after inclusion
|
Overall survival
Aikaikkuna: From date of randomization until the date of death from any cause, whichever came first, assessed up to 100 months
|
Overall survival defined as time interval between randomization and death (all causes).
Alive patients will be censored at the last date of news or data cut off
|
From date of randomization until the date of death from any cause, whichever came first, assessed up to 100 months
|
Tumoral response
Aikaikkuna: every 6-9 weeks
|
Tumoral response (complete response, partial response, stable disease, progression) according to RECIST 1.1
|
every 6-9 weeks
|
Toxicities
Aikaikkuna: From date of randomization until study participation, assessed up to 100 months
|
Toxicities according to NCI-CTC-AE v.4
|
From date of randomization until study participation, assessed up to 100 months
|
Rebound phenomenon (flare)
Aikaikkuna: within 3 weeks after disease progression before inclusion
|
Rebound phenomenon (flare) defined by a hospitalization or a death within 3 weeks for disease progression after the end of TKI EGFR treatment (in the arm without EGFR TKI) and date of onset
|
within 3 weeks after disease progression before inclusion
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Radj GERVAIS, MD, Centre François Baclesse - CAEN- FRANCE
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Hengityselinten sairaudet
- Neoplasmat
- Keuhkosairaudet
- Neoplasmat sivustoittain
- Hengitysteiden kasvaimet
- Rintakehän kasvaimet
- Syöpä, bronkogeeninen
- Keuhkoputkien kasvaimet
- Keuhkojen kasvaimet
- Karsinooma, ei-pienisoluinen keuhko
- Farmakologisen vaikutuksen molekyylimekanismit
- Entsyymin estäjät
- Antineoplastiset aineet
- Proteiinikinaasin estäjät
- Erlotinibihydrokloridi
Muut tutkimustunnusnumerot
- FLARE /GFPC 03-2013
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset ERLOTINIB WITH CHEMOTHERAPY
-
Stanford UniversityAktiivinen, ei rekrytointiResilienssi, psykologinen | Puettavat laitteet | Psykologinen hyvinvointi | Henkilökohtainen ja ammatillinen toteutus | MultiomiikkaYhdysvallat
-
King's College LondonRekrytointiMaksasairaudet | Sydänsairaudet | Sydämen vajaatoiminta | Aivohalvaus | Aivoverenkiertohäiriöt | Epilepsia | Kipu | Multippeliskleroosi | Hypertensio | Lihavuus | Diabetes | Syöpä | Niveltulehdus | Nivelrikko | Nivelreuma | Parkinsonin tauti | Migreeni | Hepatiitti | Eteisvärinä | Astma | Endometrioosi | Dementia | Fibromyalgia | Keliakia | Ekseema | PCOS | S... ja muut ehdotYhdistynyt kuningaskunta
-
Hasselt UniversityValmisMultippeliskleroosiBelgia
-
University of ManitobaCancerCare ManitobaAktiivinen, ei rekrytointiSyöpä | Kognitiivinen rajoite | Kognitiivinen toimintahäiriö | Nuoret | Nuoret aikuisetKanada
-
University Hospital, GhentUniversiteit AntwerpenValmisSiirtymävaiheen hoito | Synnynnäinen sydänsairaus teini-iässäBelgia
-
The Hong Kong Polytechnic UniversityValmisLaite tehotonHong Kong
-
The Hong Kong Polytechnic UniversityAktiivinen, ei rekrytointi
-
Medical University of South CarolinaValmisAnemia, sirppisoluYhdysvallat
-
Dana-Farber Cancer InstitutePeruutettuHeikkolaatuinen glioma | Selviytymistä | Hoitoa aiheuttava taakkaYhdysvallat
-
Marshall UniversityUniversity of Toronto; University of Southern DenmarkRekrytointiNivelrikko, polviYhdysvallat